Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Hypersensitivity Reaction

Free Subscription Articles published in J Am Acad Dermatol Retrieve available abstracts of 135 articles: HTML format

Single Articles

November 2025
1. DAI Y, Wang Y, Luo H, Tan J, et al
   Association Between Endometriosis and Atopic Dermatitis: Evidence from NHANES and Genetic Causal Inference.
   J Am Acad Dermatol. 2025 Nov 27:S0190-9622(25)03285.
   PubMed    
   
   
   
2. HERRERA HO, Bordeaux JS
   Risk of Pediatric Infections Following Dupilumab Treatment for Atopic Dermatitis: A TriNetX Cohort Study.
   J Am Acad Dermatol. 2025 Nov 15:S0190-9622(25)03229.
   PubMed    
   
   
   
3. YOSIPOVITCH G, Zirwas M, Rasouliyan L, Althoff AG, et al
   Combined Impact of Lesion and Itch Severity on Initiation of Biologic Treatment in Patients with Moderate or Severe Atopic Dermatitis from Specialty Dermatology Facilities in the United States.
   J Am Acad Dermatol. 2025 Nov 12:S0190-9622(25)03187.
   PubMed    
   
   
   
4. SOOD S, Bagit A, Maliyar K, Georgakopoulos JR, et al
   Five-year real-world drug survival of dupilumab in patients with atopic dermatitis: A multicenter retrospective study.
   J Am Acad Dermatol. 2025 Nov 7:S0190-9622(25)03150.
   PubMed    
   
   
   
5. BISSONNETTE R, Agner T, Molin S, Guttman-Yassky E, et al
   Hand eczema-Part 1: Epidemiology, pathogenesis, diagnosis, and work-up.
   J Am Acad Dermatol. 2025;93:1201-1210.
   PubMed     Abstract available
   
   
   October 2025
6. FISHER C, Wohltmann WE
   JAAD Game Changers: "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study".
   J Am Acad Dermatol. 2025 Oct 29:S0190-9622(25)03101.
   PubMed    
   
   
   
7. DULAI AS, Murase EM, Avallone G, Ferrucci SM, et al
   International Multi-Center Case Series of Gestational Dupilumab Exposure in the Treatment of Atopic Dermatitis: Maternal Complications and Fetal Outcomes.
   J Am Acad Dermatol. 2025 Oct 29:S0190-9622(25)03123.
   PubMed    
   
   
   
8. SEIFERT RM, Teames CR, Sahni V, Noot C, et al
   The Impact of Allergen Avoidance on Oral Lichen Planus:A Retrospective Cohort-Based Comparison.
   J Am Acad Dermatol. 2025 Oct 13:S0190-9622(25)03008.
   PubMed    
   
   
   
9. SCHNEEWEISS MC, Glynn RJ, Anand P, Jin Y, et al
   Choice of new treatment for patients with atopic dermatitis is associated with insurance status rather than race: A cross sectional study from commercial and Medicaid insurance claims databases.
   J Am Acad Dermatol. 2025 Oct 6:S0190-9622(25)02969.
   PubMed    
   
   
   
10. KANG HE, Lee A, Wang SP, Ye M, et al
    Examining the Impact of Child Atopic Dermatitis on Maternal Depression: A Longitudinal Cohort Study.
    J Am Acad Dermatol. 2025 Oct 6:S0190-9622(25)02968.
    PubMed     Abstract available
    
    
    
11. CHAN KR, Keddie SH, Flohr C, Tsoi MF, et al
    Prevalence of atopic dermatitis in the United States from 2021-2024: data from the National Health Interview Survey.
    J Am Acad Dermatol. 2025 Oct 6:S0190-9622(25)02973.
    PubMed    
    
    
    
12. ZEMLOK SK, Woodard E, Yu J
    Contact Allergens in Topical Therapies Commonly used in Eczema and Seborrheic Dermatitis: A reference guide for prescribing clinicians.
    J Am Acad Dermatol. 2025 Oct 6:S0190-9622(25)02923.
    PubMed    
    
    
    
13. LEE S, LeBovidge J, Berbert L, Barbieri JS, et al
    Validation of the Atopic Dermatitis Control Tool in Pediatric Patients with Atopic Dermatitis.
    J Am Acad Dermatol. 2025 Oct 4:S0190-9622(25)02925.
    PubMed    
    
    
    
14. HSIEH TS, Lee HY, Abe R, Takei S, et al
    Development and validation of prognostic models using novel inflammatory markers for drug reactions with eosinophilia and systemic symptoms: An international multicenter cohort study.
    J Am Acad Dermatol. 2025;93:1027-1034.
    PubMed     Abstract available
    
    
    
15. JOLY-CHEVRIER M, Alamari A, Muha J, Lachance Y, et al
    AI Chatbots for Atopic Dermatitis: Accuracy, Readability, and Concordance With AAD Guidelines.
    J Am Acad Dermatol. 2025 Oct 1:S0190-9622(25)02913.
    PubMed    
    
    
    September 2025
16. ISLAM RK, Islam KN, Haas CJ
    Response to Ting et al., "Atopic Dermatitis and Diabetes Risk: Additional Concerns.".
    J Am Acad Dermatol. 2025 Sep 29:S0190-9622(25)02912.
    PubMed    
    
    
    
17. TING CT, Chen BS, Wei JC
    Atopic Dermatitis and Diabetes Risk: Additional Concerns.
    J Am Acad Dermatol. 2025 Sep 29:S0190-9622(25)02911.
    PubMed    
    
    
    
18. BURKE SM, Beveridge M, Hatipoglu B, Murphy J, et al
    Association of GLP-1 Agonist Use with Atopic Dermatitis in Obese Patients: A Retrospective Cohort Study.
    J Am Acad Dermatol. 2025 Sep 29:S0190-9622(25)02903.
    PubMed    
    
    
    
19. ZHOU MH, Gold JAW, Hay RJ, Lipner SR, et al
    Association between atopic dermatitis and dermatophytosis: a TriNetX retrospective cohort study.
    J Am Acad Dermatol. 2025 Sep 26:S0190-9622(25)02896.
    PubMed    
    
    
    
20. HE H, Yu L, Yu B, Xu Z, et al
    Mapping the time-course and associated factors of placebo response to systemic immunomodulatory treatments for atopic dermatitis.
    J Am Acad Dermatol. 2025 Sep 23:S0190-9622(25)02879.
    PubMed    
    
    
    
21. NOEL WC 2ND, Shah A, Bercovitch L, Garza-Mayers AC, et al
    Health Insurance Coverage of Topical Medications in Vitiligo and Atopic Dermatitis.
    J Am Acad Dermatol. 2025 Sep 19:S0190-9622(25)02864.
    PubMed    
    
    
    
22. HAGINO T, Uchiyama A, Kosaka K, Araki T, et al
    A 48-week real-world outcome of tralokinumab treatment for atopic dermatitis: Systemic therapy-naive versus -experienced patients.
    J Am Acad Dermatol. 2025 Sep 15:S0190-9622(25)02822.
    PubMed    
    
    
    
23. LU J, Wang Y, Zhou C, Deng L, et al
    Increased Cancer Risk and Mortality in Individuals with Atopic Dermatitis: Evidence from the NHANES.
    J Am Acad Dermatol. 2025 Sep 1:S0190-9622(25)02726.
    PubMed    
    
    
    August 2025
24. CHANG JW, Wang F
    Response to Wang et al., "Comments on 'Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis'".
    J Am Acad Dermatol. 2025 Aug 29:S0190-9622(25)02699.
    PubMed    
    
    
    
25. BISSONNETTE R, Goleva E, Berdyshev E, Leung DYM, et al
    In response to: "Response to Bissonnette et al. Dupilumab treatment restores lesional and non-lesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy.
    J Am Acad Dermatol. 2025 Aug 29:S0190-9622(25)02705.
    PubMed    
    
    
    
26. CLABBERS J, Boesjes C, van Geel M, de Bruin-Weller M, et al
    Response to Bissonnette et al. 'Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, p
    J Am Acad Dermatol. 2025 Aug 29:S0190-9622(25)02703.
    PubMed    
    
    
    
27. WANG Y, Liu Z
    Comments on "Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis".
    J Am Acad Dermatol. 2025 Aug 29:S0190-9622(25)02698.
    PubMed    
    
    
    
28. SHIVE M, Hawryluk E, Drucker AM, Frazer-Green L, et al
    Response to Chu et al's "Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based r
    J Am Acad Dermatol. 2025 Aug 27:S0190-9622(25)02552.
    PubMed    
    
    
    
29. BRUSTAD N, Wang T, Chen L, Kaiser H, et al
    Effect of prenatal high-dose vitamin D on childhood atopic dermatitis is modified by maternal cotinine metabolome: A secondary analysis of a randomized clinical trial.
    J Am Acad Dermatol. 2025 Aug 25:S0190-9622(25)02670.
    PubMed     Abstract available
    
    
    
30. CHEN TL, Ma SH, Ou WF, Chen CC, et al
    Decreased Risk of Reduced Linear Growth Among Children with Atopic Dermatitis Receiving Dupilumab: A Cohort Study.
    J Am Acad Dermatol. 2025 Aug 18:S0190-9622(25)02646.
    PubMed     Abstract available
    
    
    
31. BRAUN N, Lin C, Baker N, Peacker BL, et al
    Glucagon-like peptide-1 receptor agonists mitigate the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetes.
    J Am Acad Dermatol. 2025 Aug 18:S0190-9622(25)02645.
    PubMed    
    
    
    
32. BENANDI K, Spires A, Hansen A, Linfante A, et al
    Systemic risk profiles of topical ruxolitinib and oral Janus kinase inhibitors in patients with atopic dermatitis: A retrospective cohort study from the TriNetX network.
    J Am Acad Dermatol. 2025 Aug 12:S0190-9622(25)02388.
    PubMed     Abstract available
    
    
    
33. CHANG JW, Wang F
    Response to Goleva et al., "Response to Chang et al's 'Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis'".
    J Am Acad Dermatol. 2025 Aug 7:S0190-9622(25)02558.
    PubMed    
    
    
    
34. GOLEVA E, Berdyshev E, Kreimer S, Leung DYM, et al
    Response to Chang et al's "Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis".
    J Am Acad Dermatol. 2025 Aug 6:S0190-9622(25)02557.
    PubMed    
    
    
    
35. GROLEAU AS, Mereniuk A, Makhzoum JP
    Current therapeutic options for adult patients with urticarial vasculitis: A scoping review.
    J Am Acad Dermatol. 2025;93:423-428.
    PubMed     Abstract available
    
    
    July 2025
36. HAGINO T, Saeki H, Fujimoto E, Kanda N, et al
    Effectiveness of Tralokinumab for Upadacitinib-Refractory Atopic Dermatitis: 48-week Retrospective Study.
    J Am Acad Dermatol. 2025 Jul 19:S0190-9622(25)02528.
    PubMed    
    
    
    
37. XIONG G, Gupta S, Rao V, Abu-Hilal M, et al
    Topical Ruxolitinib is More Effective at Itch Reduction than Topical Roflumilast in Atopic Dermatitis: A Comparative Meta-Analysis.
    J Am Acad Dermatol. 2025 Jul 3:S0190-9622(25)02402.
    PubMed    
    
    
    June 2025
38. WEBER B, Karels S, Shaik J, Neeley A, et al
    Formaldehyde Allergic Contact Dermatitis: Evaluation of Paper-Based Menstrual Products as a Potential Route of Exposure.
    J Am Acad Dermatol. 2025 Jun 25:S0190-9622(25)02387.
    PubMed    
    
    
    
39. SUN C, Zhang X, Su Z, Yao WH, et al
    Global, regional and national burdens of atopic dermatitis from 1990 to 2021: a trend analysis from the Global Burden of Disease Study 2021.
    J Am Acad Dermatol. 2025 Jun 19:S0190-9622(25)02369.
    PubMed     Abstract available
    
    
    
40. DAVIS DMR, Frazer-Green L, Alikhan A, Bercovitch L, et al
    Focused update: Guidelines of care for the management of atopic dermatitis in adults.
    J Am Acad Dermatol. 2025 Jun 17:S0190-9622(25)02125.
    PubMed     Abstract available
    
    
    
41. MANN C, Wollenberg A, Stander S, Staubach P, et al
    Risk of developing sleep disorders and psychologic comorbidity in children with inflammatory skin diseases-A population-based study.
    J Am Acad Dermatol. 2025;92:1261-1268.
    PubMed     Abstract available
    
    
    May 2025
42. PALLER AS, Siegfried EC, Cork MJ, Kabashima K, et al
    Efficacy and safety of dupilumab in pediatric patients aged 6 months to 11 years with erythrodermic atopic dermatitis: A post-hoc analysis of three clinical trials.
    J Am Acad Dermatol. 2025 May 27:S0190-9622(25)02204.
    PubMed    
    
    
    
43. RIGALI S, Liszewski W
    Allergens in hair relaxer products: a potential source of allergic contact dermatitis in patients with textured hair.
    J Am Acad Dermatol. 2025 May 22:S0190-9622(25)02191.
    PubMed    
    
    
    
44. BISSONNETTE R, Gold LS, Kircik L, Simpson EL, et al
    Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis.
    J Am Acad Dermatol. 2025 May 16:S0190-9622(25)02130.
    PubMed     Abstract available
    
    
    
45. EICHENFIELD LF, Stein Gold LF, Simpson EL, Zaenglein AL, et al
    Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study.
    J Am Acad Dermatol. 2025 May 14:S0190-9622(25)02124.
    PubMed    
    
    
    
46. KARELS S, Weber B, Ophaug S, Lee K, et al
    Evaluation of Nickel Content in Commercial Razors: Implications for Dermatologic Management of Nickel Allergy.
    J Am Acad Dermatol. 2025 May 10:S0190-9622(25)02107.
    PubMed    
    
    
    
47. ISLAM RK, Magharehabed Y, Islam KN, Joseph JM, et al
    Increased risk of type 2 diabetes in patients with atopic dermatitis: An age-stratified analysis using TriNetX.
    J Am Acad Dermatol. 2025 May 7:S0190-9622(25)00709.
    PubMed    
    
    
    
48. KALTCHENKO M, Radtke S, Kim E, Wan J, et al
    Response to Lai and Wei's "Comment on Kaltchenko et al.'s 'Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: A real-world cohort analysis.".
    J Am Acad Dermatol. 2025 May 5:S0190-9622(25)00692.
    PubMed    
    
    
    
49. LAI IC, Wei JC
    Comment on Kaltchenko et al.'s "Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: A real-world cohort analysis.".
    J Am Acad Dermatol. 2025 May 4:S0190-9622(25)00691.
    PubMed    
    
    
    April 2025
50. JOSHI A, Gawey L, Rahman M, Ghanshani R, et al
    Post-Marketing Safety Analysis of Upadacitinib in Atopic Dermatitis: An FDA Adverse Reporting System (FAERS) Review of Boxed Warning Related Adverse Events.
    J Am Acad Dermatol. 2025 Apr 25:S0190-9622(25)00681.
    PubMed    
    
    
    
51. CHANG JW, Huang X, Jiang W, Lun L, et al
    Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis.
    J Am Acad Dermatol. 2025 Apr 15:S0190-9622(25)00621.
    PubMed     Abstract available
    
    
    
52. JIN Y
    Considerations on the Potential Link Between Dupilumab and Cutaneous T-cell Lymphoma in Atopic Dermatitis.
    J Am Acad Dermatol. 2025 Apr 4:S0190-9622(25)00563.
    PubMed    
    
    
    
53. NICHOLAS A, Fleischer AB Jr
    Race and appointment availability influence continuity of care for chronic inflammatory skin disease: A cross-sectional study of United States practice data.
    J Am Acad Dermatol. 2025;92:753-760.
    PubMed     Abstract available
    
    
    
54. LI R, Zhang J, Wang L, Zhang LY, et al
    Comments on "Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: a real-world cohort analysis".
    J Am Acad Dermatol. 2025 Apr 1:S0190-9622(25)00554.
    PubMed    
    
    
    
55. KALTCHENKO M, Kim E, Radtke S, Wan J, et al
    Response to Li et al.'s "Comments on 'Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: A real-world cohort analysis".
    J Am Acad Dermatol. 2025 Apr 1:S0190-9622(25)00555.
    PubMed    
    
    
    March 2025
56. KANTOR J
    This Month in JAAD International: June 2025: Atopic dermatitis, puberty, and the benefits of nationwide cohort studies.
    J Am Acad Dermatol. 2025 Mar 29:S0190-9622(25)00551.
    PubMed    
    
    
    
57. HERMAN KE, Beck LA, Jarvinen KM
    Updates to the role of diet in atopic dermatitis.
    J Am Acad Dermatol. 2025 Mar 29:S0190-9622(25)00550.
    PubMed    
    
    
    
58. YOUN CG, Pour Mohammad A, Marqueling AL, Siegel DH, et al
    Association Between Supplemental Nutrition Assistance Program (SNAP) and Cost-Related Medical Care Delays in Pediatric Atopic Dermatitis: A Cross-Sectional Analysis of the National Health Interview Survey, 1999-2018.
    J Am Acad Dermatol. 2025 Mar 15:S0190-9622(25)00446.
    PubMed    
    
    
    
59. GUPTA S, Xiong G, Shenouda C, Keow S, et al
    Ruxolitinib versus Roflumilast: A Meta-analysis of the Comparative Efficacy of Two Topical Therapies for Atopic Dermatitis.
    J Am Acad Dermatol. 2025 Mar 14:S0190-9622(25)00438.
    PubMed    
    
    
    February 2025
60. DAHABREH D, Lo JC, Chandra M, Chiou AS, et al
    Atopic Dermatitis Prevalence among Asian American and Pacific Islander Children: A Retrospective Study in a Northern California Healthcare System.
    J Am Acad Dermatol. 2025 Feb 9:S0190-9622(25)00256.
    PubMed    
    
    
    
61. LIAO V, Lavin L, Pulitzer MP, Stuver R, et al
    Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis: A retrospective cohort study from a single tertiary cancer center.
    J Am Acad Dermatol. 2025 Feb 1:S0190-9622(25)00188.
    PubMed    
    
    
    
62. RAU A, Leahr G, Del Pozo D, Hoffstad O, et al
    Atopic Dermatitis: Association of maternal and child history of celiac disease and the child's development of atopic dermatitis.
    J Am Acad Dermatol. 2025 Feb 1:S0190-9622(25)00178.
    PubMed    
    
    
    January 2025
63. LI Z, Xiao Y, Chen X, Gu X, et al
    Temporal Trends in the Prevalence and Burden of Atopic Dermatitis Worldwide from 1990 to 2021.
    J Am Acad Dermatol. 2025 Jan 31:S0190-9622(25)00163.
    PubMed    
    
    
    
64. SANDLER M, Kim EJ, Chen LC, Yu J, et al
    Discrepancies in Patch Testing Timing and Outcomes: A Retrospective Analysis of the Pediatric Allergic Contact Dermatitis Registry.
    J Am Acad Dermatol. 2025 Jan 31:S0190-9622(25)00165.
    PubMed    
    
    
    
65. HAGINO T, Saeki H, Fujimoto E, Kanda N, et al
    A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy-naive versus -experienced patients.
    J Am Acad Dermatol. 2025 Jan 27:S0190-9622(25)00132.
    PubMed     Abstract available
    
    
    
66. SOOD S, Wiseman M, Bagit A, Maliyar K, et al
    Real-world experience of tralokinumab for atopic dermatitis: A 16-week multicenter retrospective study.
    J Am Acad Dermatol. 2025 Jan 24:S0190-9622(25)00131.
    PubMed    
    
    
    
67. BISSONNETTE R, Goleva E, Berdyshev E, Garcia S, et al
    Dupilumab treatment restores lesional and non-lesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD
    J Am Acad Dermatol. 2025 Jan 22:S0190-9622(25)00113.
    PubMed    
    
    
    
68. RODRIGUEZ R, Szeto MD, Hydol-Smith J, Burnette C, et al
    Higher Odds of Dupilumab Prescriptions for Black Patients with Atopic Dermatitis: Results of a Retrospective Study Using DataDerm, The Database of The American Academy of Dermatology.
    J Am Acad Dermatol. 2025 Jan 21:S0190-9622(25)00105.
    PubMed    
    
    
    
69. KALTCHENKO M, Radtke S, Kim E, Wan J, et al
    Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: a real-world cohort analysis.
    J Am Acad Dermatol. 2025 Jan 18:S0190-9622(25)00104.
    PubMed    
    
    
    
70. PHAN S, Hajek A, Rangel SM, Ren Z, et al
    Stigma Underlies the Mental Health Burden of Pediatric Atopic Dermatitis: A Cohort Study.
    J Am Acad Dermatol. 2025 Jan 3:S0190-9622(25)00004.
    PubMed    
    
    
    December 2024
71. GUTTMAN-YASSKY E, Rosmarin D, de Bruin-Weller M, Weidinger S, et al
    The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials.
    J Am Acad Dermatol. 2024 Dec 27:S0190-9622(24)03414.
    PubMed     Abstract available
    
    
    
72. WU PA, Wu J, Liu R, Sullivan S, et al
    Epidermal spongiotic Langerhans cell collections, but not eosinophils, are a clue to the diagnosis of allergic contact dermatitis: A series of 170 clinically- and patch test-confirmed cases.
    J Am Acad Dermatol. 2024 Dec 19:S0190-9622(24)03379.
    PubMed     Abstract available
    
    
    November 2024
73. BRODELL RT
    JAAD Game Changers: "Diet in dermatology: Part I. Atopic dermatitis, acne, and nonmelanoma skin cancer".
    J Am Acad Dermatol. 2024 Nov 28:S0190-9622(24)03276.
    PubMed    
    
    
    
74. CHOI UE, Deng J, Parthasarathy V, Liao V, et al
    Risk factors and temporal associations of progression of the atopic march in children with early-onset atopic dermatitis.
    J Am Acad Dermatol. 2024 Nov 28:S0190-9622(24)03273.
    PubMed     Abstract available
    
    
    
75. MASISON J, Beltrami EJ, Gronbeck C, Feng H, et al
    Differential patient travel burden to pediatric atopic dermatitis clinical trial sites.
    J Am Acad Dermatol. 2024 Nov 8:S0190-9622(24)03109.
    PubMed    
    
    
    October 2024
76. SINGAL A, Lipner HI, Neubauer Z, Lipner SR, et al
    Higher Sodium Excretion Is Not Associated With Increased Odds of Developing Atopic Dermatitis in a Large Retrospective Cohort Study.
    J Am Acad Dermatol. 2024 Oct 21:S0190-9622(24)03032.
    PubMed    
    
    
    
77. PALLER AS, de Bruin-Weller M, Marcoux D, Baselga E, et al
    Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDISTAD.
    J Am Acad Dermatol. 2024 Oct 8:S0190-9622(24)02919.
    PubMed     Abstract available
    
    
    
78. ELGHAZZAWY MB, Nassir S, Arora JS, Min MS, et al
    A retrospective cohort study investigating cutaneous vasculitis in the setting of COVID-19 notes higher rates of IgA vasculitis.
    J Am Acad Dermatol. 2024;91:757-759.
    PubMed    
    
    
    
79. OBIJIOFOR CE, Sikora M, Liu L, Stern MJ, et al
    Investigating corrected QT prolongation with hydroxychloroquine use among patients with cutaneous sarcoidosis: A multicenter retrospective study.
    J Am Acad Dermatol. 2024;91:740-742.
    PubMed    
    
    
    September 2024
80. NGUYEN TV, Marcus AF, Sinnott SJ, Coleman A, et al
    Commentary: Response to "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study".
    J Am Acad Dermatol. 2024 Sep 30:S0190-9622(24)02901.
    PubMed    
    
    
    
81. PALLER AS, Silverberg JI, Simpson EL, Cork MJ, et al
    The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study.
    J Am Acad Dermatol. 2024 Sep 28:S0190-9622(24)02896.
    PubMed     Abstract available
    
    
    
82. GUILLEMIN C, Bellon N, Jachiet M, Barbarot S, et al
    Dupilumab in atopic-dermatitis-like eczema associated with inborn errors of immunity: a nationwide study.
    J Am Acad Dermatol. 2024 Sep 27:S0190-9622(24)02885.
    PubMed    
    
    
    
83. NEUBAUER ZJK, Brunner PM, Geskin LJ, Guttman E, et al
    Decoupling the Association of Dupilumab with Cutaneous T-Cell Lymphoma Reply to "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study.".
    J Am Acad Dermatol. 2024 Sep 7:S0190-9622(24)02812.
    PubMed    
    
    
    
84. MATEI I, Bettuzzi T, Peiffer B, Ingen-Housz-Oro S, et al
    Evolution of the spectrum of drugs associated with acute generalized exanthematous pustulosis over time: A pharmacovigilance study.
    J Am Acad Dermatol. 2024;91:555-557.
    PubMed    
    
    
    
85. INGEN-HOUSZ-ORO S, Guichard E, Milpied B, Bensaid B, et al
    Topical versus oral corticosteroids in moderate drug reaction with eosinophilia and systemic symptoms: A multicenter randomized clinical trial.
    J Am Acad Dermatol. 2024;91:544-547.
    PubMed    
    
    
    August 2024
86. MA EZ, Bao A, Ahmadi M, Zhang J, et al
    Dupilumab is associated with reduced risk of acute upper respiratory infections in atopic dermatitis patients compared to non-targeted immunosuppressants: a multi-center cohort study.
    J Am Acad Dermatol. 2024 Aug 30:S0190-9622(24)02756.
    PubMed    
    
    
    
87. HASAN I, Zinn Z
    Response to Flynn et al. "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Aug 27:S0190-9622(24)02727.
    PubMed    
    
    
    
88. CHO YT, Chu CY
    Comments on "dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T-cell lymphoma: a retrospective cohort study".
    J Am Acad Dermatol. 2024 Aug 24:S0190-9622(24)02739.
    PubMed    
    
    
    
89. FLYNN E, Leonard N, Svoboda R
    Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Aug 23:S0190-9622(24)02726.
    PubMed    
    
    
    
90. CHAIYABUTR C, Dawe R, Lesar A, Ibbotson SH, et al
    Continuum of Light Sensitivity in Atopic Dermatitis: A Retrospective Analysis of 139 Cases in Scotland.
    J Am Acad Dermatol. 2024 Aug 22:S0190-9622(24)02710.
    PubMed     Abstract available
    
    
    
91. SEE TOW HX, Yeok-Loo Lim A, Ci-En Choi E
    Response to: Bocquel et al., "Impact of dupilumab on patch test results and allergic contact dermatitis: A prospective multicenter study".
    J Am Acad Dermatol. 2024 Aug 21:S0190-9622(24)02661.
    PubMed    
    
    
    
92. GEORGE SE, Yu J
    Tralokinumab as an Effective Alternative after Dupilumab Treatment Failure in Moderate-to-Severe Atopic Dermatitis: A Real-World Study.
    J Am Acad Dermatol. 2024 Aug 20:S0190-9622(24)02700.
    PubMed    
    
    
    
93. RIVA HR, Woodruff CM
    Allergens and consumer warnings in at-home acrylic manicure kits.
    J Am Acad Dermatol. 2024 Aug 13:S0190-9622(24)02655.
    PubMed    
    
    
    
94. KRIDIN K, Ludwig RJ
    Reply to: "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study".
    J Am Acad Dermatol. 2024 Aug 6:S0190-9622(24)02574.
    PubMed    
    
    
    
95. CHEN TL, Ma SH
    Comments on the risk of cutaneous T cell lymphoma among patients with atopic dermatitis receiving dupilumab.
    J Am Acad Dermatol. 2024 Aug 6:S0190-9622(24)02573.
    PubMed    
    
    
    
96. HEYMANN WR
    Dupilumab's duplicity.
    J Am Acad Dermatol. 2024;91:249-250.
    PubMed    
    
    
    
97. SAMARAKOON U, Wolfson AR, Zhou L, Bassir F, et al
    Understanding the patient experience of drug reaction with eosinophilia and systemic symptoms: A qualitative study.
    J Am Acad Dermatol. 2024;91:370-373.
    PubMed    
    
    
    
98. GEORGE SE, Yu J
    Patch testing outcomes in children at the Massachusetts General Hospital.
    J Am Acad Dermatol. 2024;91:354-356.
    PubMed    
    
    
    July 2024
99. ZIEBART RL, Haberecht H, Davis MD, Wetter DA, et al
    Vancomycin-Associated Drug induced Hypersensitivity Syndrome: A Retrospective Cohort Study.
    J Am Acad Dermatol. 2024 Jul 29:S0190-9622(24)02556.
    PubMed    
    
    
    
100. PEZZOLO E, Narcisi A, Gargiulo L, Di Lernia V, et al
     Successful response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: a multicenter case series study.
     J Am Acad Dermatol. 2024 Jul 22:S0190-9622(24)02538.
     PubMed    
     
     
     
101. ZHAO Y, Zhang L, Zhang J
     Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
     J Am Acad Dermatol. 2024 Jul 20:S0190-9622(24)02498.
     PubMed    
     
     
     
102. WU KJ, Wei KC
     Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
     J Am Acad Dermatol. 2024 Jul 19:S0190-9622(24)02496.
     PubMed    
     
     
     
103. MEROLA JF, Chiou AS, During E, Foley P, et al
     Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPISTAD study.
     J Am Acad Dermatol. 2024 Jul 13:S0190-9622(24)02483.
     PubMed    
     
     
     
104. SHIH PC, Wei JCC
     Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
     J Am Acad Dermatol. 2024 Jul 11:S0190-9622(24)01041.
     PubMed    
     
     
     
105. HASAN I, Zinn Z
     Response to Shih et al. "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
     J Am Acad Dermatol. 2024 Jul 10:S0190-9622(24)01046.
     PubMed    
     
     
     
106. MCKENZIE NC, Buras MR, Yiannias JA, Hall MR, et al
     Cost-effectiveness of patch testing allergens within the same group - a computational approach to optimize formaldehyde-related allergen selection.
     J Am Acad Dermatol. 2024 Jul 5:S0190-9622(24)01000.
     PubMed     Abstract available
     
     
     
107. BAO A, Su HJ, Wan J
     Comparative Safety Analysis of Anti-IL-4/IL-13 Inhibitors and JAK Inhibitors in Atopic Dermatitis.
     J Am Acad Dermatol. 2024 Jul 4:S0190-9622(24)01003.
     PubMed    
     
     
     
108. BRODELL RT
     JAAD Game Changer: Etanercept therapy for toxic epidermal necrolysis.
     J Am Acad Dermatol. 2024;91:191.
     PubMed    
     
     
     June 2024
109. GRANT-KELS JM
     JAAD Game Changers: "Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate".
     J Am Acad Dermatol. 2024 Jun 13:S0190-9622(24)00901.
     PubMed    
     
     
     
110. LIN TL, Fan YH, Fan KS, Juan CK, et al
     Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study.
     J Am Acad Dermatol. 2024 Jun 13:S0190-9622(24)00788.
     PubMed     Abstract available
     
     
     
111. KEOW S, Abu-Hilal M
     Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study.
     J Am Acad Dermatol. 2024 Jun 8:S0190-9622(24)00891.
     PubMed    
     
     
     
112. GANTZ HY, Greenzaid JD, Feldman SR
     Atopic dermatitis may not confer clinically meaningful risk of inflammatory bowel disease or renal malignancy.
     J Am Acad Dermatol. 2024 Jun 4:S0190-9622(24)00841.
     PubMed    
     
     
     
113. YAMANAKA-TAKAICHI M, Watanabe M, Comfere NI, Sokumbi O, et al
     Differentiating generalized pustular psoriasis from acute generalized exanthematous pustulosis.
     J Am Acad Dermatol. 2024;90:1289-1291.
     PubMed    
     
     
     
114. CURTIS KK, Dillan MM, Sharma TR, Piktel J, et al
     COVID-19 infection increases the development of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort analysis.
     J Am Acad Dermatol. 2024;90:1300-1302.
     PubMed    
     
     
     
115. WANG S, Laageide L, Phan V, Rosenbach M, et al
     Use of registry surveys in cutaneous sarcoidosis.
     J Am Acad Dermatol. 2024;90:1294-1296.
     PubMed    
     
     
     
116. SIMPSON EL, Silverberg JI, Worm M, Honari G, et al
     Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
     J Am Acad Dermatol. 2024;90:1190-1199.
     PubMed     Abstract available
     
     
     
117. PATTERSON A
     JAAD Game Changer: Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: A retrospective study.
     J Am Acad Dermatol. 2024;90:1318.
     PubMed    
     
     
     
118. ELSTON DM
     Letter from the Editor: Drug reaction with eosinophilia and systemic symptoms syndrome.
     J Am Acad Dermatol. 2024;90:1153-1154.
     PubMed    
     
     
     
119. BLUMENTHAL KG, Alvarez-Arango S, Kroshinsky D, Lo YC, et al
     Drug reaction eosinophilia and systemic symptoms: Clinical phenotypic patterns according to causative drug.
     J Am Acad Dermatol. 2024;90:1240-1242.
     PubMed    
     
     
     May 2024
120. RIGALI S, Cozzi C, Liszewski W
     Identification of the Pigments Used in Permanent Makeup and Their Ability to Elicit Allergic Contact Dermatitis.
     J Am Acad Dermatol. 2024 May 31:S0190-9622(24)00830.
     PubMed     Abstract available
     
     
     
121. WOHLTMANN WE
     JAAD Game Changers: "Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study".
     J Am Acad Dermatol. 2024 May 30:S0190-9622(24)00824.
     PubMed    
     
     
     
122. UBUKATA N, Hashizume H, Nakatani E, Sasaki H, et al
     Risk Factors and Drugs Associated with the Development of Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Population-Based Cohort Study Using the Shizuoka Kokuho Database.
     J Am Acad Dermatol. 2024 May 23:S0190-9622(24)00816.
     PubMed    
     
     
     
123. SILVERBERG JI, Eichenfield LF, Hebert AA, Simpson EL, et al
     Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials.
     J Am Acad Dermatol. 2024 May 20:S0190-9622(24)00755.
     PubMed     Abstract available
     
     
     
124. ELSTON DM
     This month in JAAD: May 2024.
     J Am Acad Dermatol. 2024;90:930.
     PubMed    
     
     
     
125. SILVERBERG JI, Kirsner RS, Margolis DJ, Tharp M, et al
     Efficacy and safety of crisaborole ointment, 2%, in participants aged >/=45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
     J Am Acad Dermatol. 2024;90:945-952.
     PubMed     Abstract available
     
     
     
126. ZHANG L, Li X, Xu X, Le Y, et al
     Ixekizumab-induced urticaria is associated with the short duration of remission in psoriasis by activation of mast cells.
     J Am Acad Dermatol. 2024;90:970-976.
     PubMed     Abstract available
     
     
     
127. SAKUNCHOTPANIT G, Rohan TZ, Milosavljevic S, Patil MK, et al
     Procalcitonin: A potentially useful serum test in patients with dermatologic disease.
     J Am Acad Dermatol. 2024;90:1090-1091.
     PubMed    
     
     
     
128. WOHLTMANN WE
     JAAD Game Changer: Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients.
     J Am Acad Dermatol. 2024;90:1114.
     PubMed    
     
     
     April 2024
129. ZHANG J, Boesjes CM, Loman L, Kamphuis E, et al
     Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry.
     J Am Acad Dermatol. 2024 Apr 21:S0190-9622(24)00641.
     PubMed     Abstract available
     
     
     
130. LEIBOWITZ R, Fischer A, Collins LF, Feldman RJ, et al
     HIV-related exclusion criteria in atopic dermatitis and prurigo nodularis clinical trials.
     J Am Acad Dermatol. 2024 Apr 12:S0190-9622(24)00633.
     PubMed    
     
     
     
131. HASAN I, Parsons L, Duran S, Zinn Z, et al
     Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.
     J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00566.
     PubMed     Abstract available
     
     
     
132. POWERS CM, Piontkowski AJ, Orloff J, Pulsinelli J, et al
     Risk of lymphoma in patients with atopic dermatitis: A case-control study in the All of Us database.
     J Am Acad Dermatol. 2024 Apr 4:S0190-9622(24)00554.
     PubMed    
     
     
     March 2024
133. MANZAR D, Suntres E, Nair N, Patel Y, et al
     Elevation of Creatine Phosphokinase in Moderate-Severe Atopic Dermatitis is Associated with the use of JAK inhibitors but not Dupilumab: A Systematic Review and Meta-Analysis.
     J Am Acad Dermatol. 2024 Mar 28:S0190-9622(24)00538.
     PubMed    
     
     
     
134. HREN MG, Guenin S, Khattri S
     Successful use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease.
     J Am Acad Dermatol. 2024 Mar 15:S0190-9622(24)00492.
     PubMed    
     
     
     October 2023
135. RONNSTAD ATM, Thomsen SF, Thyssen JP, Egeberg A, et al
     The burden of head-and-neck dermatitis in adults with atopic dermatitis and its association with asthma, rhinitis, and disease severity.
     J Am Acad Dermatol. 2023 Oct 28:S0190-9622(23)03046.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge.